PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-8.07%
Negative revenue growth while AVGO stands at 14.60%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-8.02%
Negative gross profit growth while AVGO is at 13.49%. Joel Greenblatt would examine cost competitiveness or demand decline.
-27.22%
Negative EBIT growth while AVGO is at 21.43%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-27.22%
Negative operating income growth while AVGO is at 21.43%. Joel Greenblatt would press for urgent turnaround measures.
-16.79%
Negative net income growth while AVGO stands at 21.13%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-17.65%
Negative EPS growth while AVGO is at 21.05%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-15.66%
Negative diluted EPS growth while AVGO is at 21.43%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.35%
Share reduction while AVGO is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.09%
Reduced diluted shares while AVGO is at 0.40%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
148.51%
OCF growth above 1.5x AVGO's 54.74%. David Dodd would confirm a clear edge in underlying cash generation.
194.77%
FCF growth above 1.5x AVGO's 115.28%. David Dodd would verify if the firm’s strategic investments yield superior returns.
91.29%
10Y revenue/share CAGR above 1.5x AVGO's 42.47%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
-17.64%
Negative 5Y CAGR while AVGO stands at 42.47%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
1.38%
3Y revenue/share CAGR under 50% of AVGO's 25.90%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
193.99%
10Y OCF/share CAGR above 1.5x AVGO's 60.47%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
59.86%
5Y OCF/share CAGR is similar to AVGO's 60.47%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
486.12%
Positive 3Y OCF/share CAGR while AVGO is negative. John Neff might see a big short-term edge in operational efficiency.
176.80%
Below 50% of AVGO's 724.55%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-39.42%
Negative 5Y net income/share CAGR while AVGO is 724.55%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
19.44%
3Y net income/share CAGR above 1.5x AVGO's 2.34%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
319.49%
10Y equity/share CAGR 1.25-1.5x AVGO's 219.27%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
65.02%
Below 50% of AVGO's 219.27%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
63.01%
3Y equity/share CAGR at 50-75% of AVGO's 87.12%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.09%
AR growth is negative/stable vs. AVGO's 14.52%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
-2.17%
Inventory is declining while AVGO stands at 0.35%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
5.55%
Asset growth at 75-90% of AVGO's 6.75%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
2.58%
Under 50% of AVGO's 5.87%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-3.20%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
4.87%
R&D growth drastically higher vs. AVGO's 6.93%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
3.75%
SG&A growth well above AVGO's 5.26%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.